Beautiful Virgin Islands

Sunday, Oct 19, 2025

Coronavirus FAQs: Can I Drink Between Vaccine Doses? What Is 'Vaccine Efficacy'?

Coronavirus FAQs: Can I Drink Between Vaccine Doses? What Is 'Vaccine Efficacy'?

People who've had dose 1 are wondering ... can I have a few drinks before dose 2 or will that muck things up? Also: Do you really understand the concept of "vaccine efficacy"? It's complicated!
I have started hearing that vaccine recipients should abstain from alcohol between the first and second doses of the COVID vaccine. Is this a thing?


It's true that chronic, heavy drinking and binge drinking can suppress your immune system, Kennedy says. And there are plenty of health reasons not to drink alcohol, he adds. But an occasional drink here and there — including a celebratory toast after your second shot? "That won't have an effect," he says.

What, exactly, does it mean that a vaccine is, for example, 92% efficacious? Does it mean there's an 8% chance of my getting COVID-19? If so, why would anyone want to get a vaccine that's only 60 or 65% efficacious?


I find the subject of vaccine efficacy very confusing!


Don't worry: If you find it confusing, you're probably on the right track! Efficacy rates (and effectiveness rates and point estimates and confidence intervals) should appear at least a little confusing to most non-biostatisticians. The concepts rely on statistical thinking that many aren't familiar with, says Brianne Barker, a virologist at Drew University.

The tendency to oversimplify has led many people to the same — mistaken — conclusion that an efficacy rate of 92 percent would mean that of 100 vaccinated people, 8 of them would get sick during a pandemic.

But that's not the case. Fortunately, a vaccine with a 92 percent efficacy rate actually means your chances of getting the disease is much, much less than 8 percent. It means that if you were exposed to the disease, your chances of getting infected would be 92 percent less if you were vaccinated than if you weren't.

If you want to geek out on the exact math on how much your chances of getting COVID drops after a vaccine, you'd have to know what the probability of getting sick is, Barker says. "And that varies based on the population that you look at."

Say you originally had a 10% chance of getting sick without being vaccinated. If you got that vaccine with an efficacy rate of 92%, your chance of getting sick would drop from 10% to less than 1% — 0.8%, to be exact.

In reality, the trials found that the probability of getting sick in the placebo groups was much less than 10%. In the Pfizer trial, for example, it was 0.79% — or less than one per 100 people. Participants who got the real vaccine had just a .04 percent chance of getting COVID ... that's 4 in 10,000 people.

While efficacy rates should, theoretically, make comparisons among different vaccines possible, a number of variables have made it more like "comparing an efficacy rate of 70 percent to purple," says Richard Kennedy, professor of medicine at the Mayo Clinic in Rochester, Minn., and co-director of the Vaccine Research Group.

"You're laughing because that's a ludicrous comparison," he says. But to truly make an apples-to-apples comparison, he says, you'd have to run the vaccines head-to-head in the same clinical trial. As it was, the characteristics of the participants in the various trials were different (Johnson & Johnson enrolled more people at higher risk, for example), variants were circulating during some trials and not others, and each trial defined the disease differently. (For example, Moderna defined a COVID-19 infection as a positive PCR test plus two symptoms from one group or one symptom from another group. Pfizer defined it as a positive PCR test plus one symptom.)

"The devil really is in the details," he says.

Can I get the Johnson & Johnson vaccine and then sign up for Pfizer or Moderna?


Theoretically, that should be fine, Barker and Kennedy agree. In real life, it's unlikely to happen — "it's hard enough to get one in the first place," Barker says, and "having already received one shot of Johnson & Johnson, you'd be considered fully vaccinated and probably no one is going to let you get another one because you're taking it away from someone who needs it," Kennedy says.

However, your body would likely handle the mixing and matching just fine, since all of the vaccines have the same antigen, Kennedy explains. The antigen is the component that your immune response recognizes — in this case, the spike protein. It's akin to the flu vaccine, he says. We get influenza vaccines every year, often with similar strains, without worrying about which company made it. When antigens are different, however, your body usually develops weaker antibodies.

"Another thing to consider is what will happen if we need booster doses in 6 months, 2 years, whenever," he says. "I doubt that we will have the resources or ability to only provide the same vaccine that you originally received."

And can people who have an allergic reaction to their first Pfizer or Moderna shot follow up with Johnson & Johnson?


Again, this may work in theory, Kennedy says, but until vaccines are more widely available it may not be possible. In the meantime, be reassured that your first dose may provide pretty good protection. After all, the Pfizer and Moderna vaccines weren't studied as single doses, so the efficacy rate after a month or two could be higher than you think, he points out.

Newsletter

Related Articles

Beautiful Virgin Islands
0:00
0:00
Close
Windows’ Own ‘Siri’ Has Arrived: You Can Now Talk to Your Computer
Thailand and Singapore Investigate Cambodian-Based Prince Group as U.S. and U.K. Sanctions Unfold
‘No Kings’ Protests Inflate Numbers — But History Shows Nations Collapse Without Strong Executive Power
Chinese Tech Giants Halt Stablecoin Launches After Beijing’s Regulatory Intervention
Manhattan Jury Holds BNP Paribas Liable for Enabling Sudanese Government Abuses
Trump Orders Immediate Release of Former Congressman George Santos After Commuting Prison Sentence
S&P Downgrades France’s Credit Rating, Citing Soaring Debt and Political Instability
Ofcom Rules BBC’s Gaza Documentary ‘Materially Misleading’ Over Narrator’s Hamas Ties
Diane Keaton’s Cause of Death Revealed as Pneumonia, Family Confirms
Former Lostprophets Frontman Ian Watkins Stabbed to Death in British Prison
"The Tsunami Is Coming, and It’s Massive": The World’s Richest Man Unveils a New AI Vision
Outsider, Heroine, Trailblazer: Diane Keaton Was Always a Little Strange — and Forever One of a Kind
Dramatic Development in the Death of 'Mango' Founder: Billionaire's Son Suspected of Murder
Two Years of Darkness: The Harrowing Testimonies of Israeli Hostages Emerging From Gaza Captivity
EU Moves to Use Frozen Russian Assets to Buy U.S. Weapons for Ukraine
Europe Emerges as the Biggest Casualty in U.S.-China Rare Earth Rivalry
HSBC Confronts Strategic Crossroads as NAB Seeks Only Retail Arm in Australia Exit
U.S. Chamber Sues Trump Over $100,000 H-1B Visa Fee
Shenzhen Expo Spotlights China’s Quantum Step in Semiconductor Self-Reliance
China Accelerates to the Forefront in Global Nuclear Fusion Race
Yachts, Private Jets, and a Picasso Painting: Exposed as 'One of the Largest Frauds in History'
Australia’s Wedgetail Spies Aid NATO Response as Russian MiGs Breach Estonian Airspace
McGowan Urges Chalmers to Cut Spending Over Tax Hike to Close $20 Billion Budget Gap
Victoria Orders Review of Transgender Prison Placement Amid Safety Concerns for Female Inmates
U.S. Treasury Mobilises New $20 Billion Debt Facility to Stabilise Argentina
French Business Leaders Decry Budget as Macron’s Pro-Enterprise Promise Undermined
Trump Claims Modi Pledged India Would End Russian Oil Imports Amid U.S. Tariff Pressure
Surging AI Startup Valuations Fuel Bubble Concerns Among Top Investors
Australian Punter Archie Wilson Tears Up During Nebraska Press Conference, Sparking Conversation on Male Vulnerability
Australia Confirms U.S. Access to Upgraded Submarine Shipyard Under AUKUS Deal
“Firepower” Promised for Ukraine as NATO Ministers Meet — But U.S. Tomahawks Remain Undecided
Brands Confront New Dilemma as Extremists Adopt Fashion Labels
The Sydney Sweeney and Jeans Storm: “The Outcome Surpassed Our Wildest Dreams”
Erika Kirk Delivers Moving Tribute at White House as Trump Awards Charlie Presidential Medal of Freedom
British Food Influencer ‘Big John’ Detained in Australia After Visa Dispute
ScamBodia: The Chinese Fraud Empire Shielded by Cambodia’s Ruling Elite
French PM Suspends Macron’s Pension Reform Until After 2027 in Bid to Stabilize Government
Orange, Bouygues and Free Make €17 Billion Bid for Drahi’s Altice France Telecom Assets
Dutch Government Seizes Chipmaker After U.S. Presses for Removal of Chinese CEO
Bessent Accuses China of Dragging Down Global Economy Amid New Trade Curbs
U.S. Revokes Visas of Foreign Nationals Who ‘Celebrated’ Charlie Kirk’s Assassination
AI and Cybersecurity at Forefront as GITEX Global 2025 Kicks Off in Dubai
DJI Loses Appeal to Remove Pentagon’s ‘Chinese Military Company’ Label
EU Deploys New Biometric Entry/Exit System: What Non-EU Travelers Must Know
Australian Prime Minister’s Private Number Exposed Through AI Contact Scraper
Ex-Microsoft Engineer Confirms Famous Windows XP Key Was Leaked Corporate License, Not a Hack
China’s lesson for the US: it takes more than chips to win the AI race
Australia Faces Demographic Risk as Fertility Falls to Record Low
California County Reinstates Mask Mandate in Health Facilities as Respiratory Illness Risk Rises
Israel and Hamas Agree to First Phase of Trump-Brokered Gaza Truce, Hostages to Be Freed
×